Bavarian Nordic (BAVA) - Net Assets
Based on the latest financial reports, Bavarian Nordic (BAVA) has net assets worth Dkr13.16 Billion DKK (≈ $2.06 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Dkr15.16 Billion ≈ $2.37 Billion USD) and total liabilities (Dkr2.00 Billion ≈ $313.01 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Bavarian Nordic (BAVA) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Dkr13.16 Billion |
| % of Total Assets | 86.8% |
| Annual Growth Rate | 24.24% |
| 5-Year Change | 133.1% |
| 10-Year Change | 749.81% |
| Growth Volatility | 78.11 |
Bavarian Nordic - Net Assets Trend (2000–2024)
This chart illustrates how Bavarian Nordic's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Bavarian Nordic for the complete picture of this company's asset base.
Annual Net Assets for Bavarian Nordic (2000–2024)
The table below shows the annual net assets of Bavarian Nordic from 2000 to 2024. For live valuation and market cap data, see BAVA company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Dkr11.41 Billion ≈ $1.78 Billion |
+10.33% |
| 2023-12-31 | Dkr10.34 Billion ≈ $1.62 Billion |
+44.61% |
| 2022-12-31 | Dkr7.15 Billion ≈ $1.12 Billion |
-3.05% |
| 2021-12-31 | Dkr7.37 Billion ≈ $1.15 Billion |
+50.68% |
| 2020-12-31 | Dkr4.89 Billion ≈ $765.76 Million |
+162.37% |
| 2019-12-31 | Dkr1.87 Billion ≈ $291.86 Million |
-14.45% |
| 2018-12-31 | Dkr2.18 Billion ≈ $341.18 Million |
-12.99% |
| 2017-12-31 | Dkr2.51 Billion ≈ $392.13 Million |
+24.24% |
| 2016-12-31 | Dkr2.02 Billion ≈ $315.61 Million |
+50.26% |
| 2015-12-31 | Dkr1.34 Billion ≈ $210.04 Million |
+7.22% |
| 2014-12-31 | Dkr1.25 Billion ≈ $195.90 Million |
+28.25% |
| 2013-12-31 | Dkr976.29 Million ≈ $152.75 Million |
-2.34% |
| 2012-12-31 | Dkr999.68 Million ≈ $156.41 Million |
-17.22% |
| 2011-12-31 | Dkr1.21 Billion ≈ $188.94 Million |
+49.01% |
| 2010-12-31 | Dkr810.43 Million ≈ $126.80 Million |
+15.08% |
| 2009-12-31 | Dkr704.21 Million ≈ $110.18 Million |
-30.63% |
| 2008-12-31 | Dkr1.02 Billion ≈ $158.82 Million |
-16.63% |
| 2007-12-31 | Dkr1.22 Billion ≈ $190.51 Million |
+76.12% |
| 2006-12-31 | Dkr691.40 Million ≈ $108.17 Million |
+9.73% |
| 2005-12-31 | Dkr630.10 Million ≈ $98.58 Million |
+99.79% |
| 2004-12-31 | Dkr315.39 Million ≈ $49.35 Million |
-9.11% |
| 2003-12-31 | Dkr347.00 Million ≈ $54.29 Million |
+76.65% |
| 2002-12-31 | Dkr196.44 Million ≈ $30.73 Million |
+345.01% |
| 2001-12-31 | Dkr44.14 Million ≈ $6.91 Million |
-29.17% |
| 2000-12-31 | Dkr62.33 Million ≈ $9.75 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Bavarian Nordic's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1043419700000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Dkr10.43 Billion | 91.46% |
| Common Stock | Dkr788.55 Million | 6.91% |
| Other Comprehensive Income | Dkr188.66 Million | 1.65% |
| Total Equity | Dkr11.41 Billion | 100.00% |
Bavarian Nordic Competitors by Market Cap
The table below lists competitors of Bavarian Nordic ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
OLAM GROUP LTD
F:K25
|
$2.30 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
$2.30 Billion |
|
Shenzhen Kangtai Biological Products Co Ltd
SHE:300601
|
$2.30 Billion |
|
Transportadora de Gas del Sur SA B
BA:TGSU2
|
$2.31 Billion |
|
SOC.BIC UNS.ADR1/2/EO382
F:BIF0
|
$2.30 Billion |
|
Yunnan Shennong Agricultural Industry Group Co Ltd
SHG:605296
|
$2.30 Billion |
|
Ziraat Gayrimenkul Yatirim Ortakligi AS
IS:ZRGYO
|
$2.30 Billion |
|
Kayne Anderson MLP Investment Closed Fund
NYSE:KYN
|
$2.30 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bavarian Nordic's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 10,339,932,000 to 11,408,561,000, a change of 1,068,629,000 (10.3%).
- Net income of 987,977,000 contributed positively to equity growth.
- Share repurchases of 27,459,000 reduced equity.
- New share issuances of 126,794,000 increased equity.
- Other comprehensive income decreased equity by 41,830,001.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Dkr987.98 Million | +8.66% |
| Share Repurchases | Dkr27.46 Million | -0.24% |
| Share Issuances | Dkr126.79 Million | +1.11% |
| Other Comprehensive Income | Dkr-41.83 Million | -0.37% |
| Other Changes | Dkr23.15 Million | +0.2% |
| Total Change | Dkr- | 10.33% |
Book Value vs Market Value Analysis
This analysis compares Bavarian Nordic's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.29x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 29.03x to 1.29x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-12-31 | Dkr6.48 | Dkr188.00 | x |
| 2002-12-31 | Dkr22.15 | Dkr188.00 | x |
| 2003-12-31 | Dkr34.62 | Dkr188.00 | x |
| 2004-12-31 | Dkr33.57 | Dkr188.00 | x |
| 2005-12-31 | Dkr57.39 | Dkr188.00 | x |
| 2006-12-31 | Dkr53.78 | Dkr188.00 | x |
| 2007-12-31 | Dkr84.07 | Dkr188.00 | x |
| 2008-12-31 | Dkr66.85 | Dkr188.00 | x |
| 2009-12-31 | Dkr55.24 | Dkr188.00 | x |
| 2010-12-31 | Dkr55.08 | Dkr188.00 | x |
| 2011-12-31 | Dkr46.08 | Dkr188.00 | x |
| 2012-12-31 | Dkr30.31 | Dkr188.00 | x |
| 2013-12-31 | Dkr29.60 | Dkr188.00 | x |
| 2014-12-31 | Dkr36.90 | Dkr188.00 | x |
| 2015-12-31 | Dkr37.13 | Dkr188.00 | x |
| 2016-12-31 | Dkr52.61 | Dkr188.00 | x |
| 2017-12-31 | Dkr62.19 | Dkr188.00 | x |
| 2018-12-31 | Dkr53.48 | Dkr188.00 | x |
| 2019-12-31 | Dkr45.71 | Dkr188.00 | x |
| 2020-12-31 | Dkr90.56 | Dkr188.00 | x |
| 2021-12-31 | Dkr116.87 | Dkr188.00 | x |
| 2022-12-31 | Dkr101.53 | Dkr188.00 | x |
| 2023-12-31 | Dkr134.79 | Dkr188.00 | x |
| 2024-12-31 | Dkr146.07 | Dkr188.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bavarian Nordic utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.66%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.28%
- • Asset Turnover: 0.40x
- • Equity Multiplier: 1.26x
- Recent ROE (8.66%) is above the historical average (-16.54%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | -208.61% | 0.00% | 0.00x | 1.40x | Dkr-96.50 Million |
| 2002 | 35.70% | 57.91% | 0.38x | 1.62x | Dkr50.48 Million |
| 2003 | 43.39% | 29.84% | 1.18x | 1.24x | Dkr115.86 Million |
| 2004 | -16.81% | -32.17% | 0.27x | 1.91x | Dkr-84.55 Million |
| 2005 | -15.08% | -38.26% | 0.27x | 1.48x | Dkr-157.55 Million |
| 2006 | -23.43% | -91.81% | 0.18x | 1.39x | Dkr-229.61 Million |
| 2007 | -5.22% | -19.12% | 0.19x | 1.42x | Dkr-185.20 Million |
| 2008 | -21.38% | -103.56% | 0.12x | 1.68x | Dkr-317.38 Million |
| 2009 | -56.23% | -529.52% | 0.06x | 1.80x | Dkr-466.41 Million |
| 2010 | -71.19% | -183.71% | 0.21x | 1.81x | Dkr-658.01 Million |
| 2011 | -26.86% | -61.94% | 0.26x | 1.64x | Dkr-445.10 Million |
| 2012 | -24.01% | -23.61% | 0.66x | 1.54x | Dkr-339.97 Million |
| 2013 | -4.79% | -3.85% | 0.83x | 1.49x | Dkr-144.36 Million |
| 2014 | 2.07% | 2.13% | 0.64x | 1.51x | Dkr-99.27 Million |
| 2015 | 4.43% | 5.82% | 0.51x | 1.48x | Dkr-74.82 Million |
| 2016 | 1.52% | 3.04% | 0.36x | 1.40x | Dkr-171.12 Million |
| 2017 | 7.24% | 13.24% | 0.43x | 1.26x | Dkr-69.29 Million |
| 2018 | -16.60% | -72.30% | 0.16x | 1.40x | Dkr-579.99 Million |
| 2019 | -18.59% | -52.34% | 0.09x | 3.78x | Dkr-533.32 Million |
| 2020 | 5.67% | 14.98% | 0.21x | 1.79x | Dkr-211.91 Million |
| 2021 | -6.30% | -24.49% | 0.16x | 1.64x | Dkr-1.20 Billion |
| 2022 | -4.86% | -11.03% | 0.25x | 1.73x | Dkr-1.06 Billion |
| 2023 | 14.27% | 20.89% | 0.49x | 1.39x | Dkr441.20 Million |
| 2024 | 8.66% | 17.28% | 0.40x | 1.26x | Dkr-152.88 Million |
Industry Comparison
This section compares Bavarian Nordic's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,643,614,000
- Average return on equity (ROE) among peers: -25.03%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bavarian Nordic (BAVA) | Dkr13.16 Billion | -208.61% | 0.15x | $2.30 Billion |
| ALK-Abelló A/S (ALK-B) | $6.45 Billion | 18.57% | 0.42x | $7.62 Billion |
| Genmab A/S (GMAB) | $659.52 Million | 17.04% | 1.63x | $16.33 Billion |
| Gubra A/S (GUBRA) | $151.46 Million | 44.85% | 0.99x | $820.85 Million |
| Pharma Equity Group A/S Cl A (PEG) | $34.28 Million | -95.90% | 0.68x | $16.36 Million |
| Zealand Pharma A/S (ZEAL) | $927.80 Million | -109.74% | 1.23x | $3.41 Billion |
About Bavarian Nordic
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an or… Read more